These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 4912184)

  • 1. Complement-fixing and fluorescent antibody responses to an attenuated Rubella virus vaccine.
    Schmidt NJ; Lennette EH
    Am J Epidemiol; 1970 Apr; 91(4):351-4. PubMed ID: 4912184
    [No Abstract]   [Full Text] [Related]  

  • 2. A controlled family study of live, attenuated rubella-virus vaccine.
    Lefkowitz LB; Rafajko RR; Federspiel CF; Quinn RW
    N Engl J Med; 1970 Jul; 283(5):229-32. PubMed ID: 4912790
    [No Abstract]   [Full Text] [Related]  

  • 3. Attenuated rubella vaccination in families: observations on the lack of fluorescent antibody response and on the use of blood collected on filter paper discs in the hemagglutination-inhibition test.
    Monto AS; Cavallaro JJ; Brown GC
    J Lab Clin Med; 1969 Jul; 74(1):98-102. PubMed ID: 4892624
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibody response to rubella virion (V) and soluble (S) antigens in rubella infection and following vaccination with live attenuated rubella virus.
    Vesikari T; Vaheri A; Leinikki P
    Arch Gesamte Virusforsch; 1971; 35(1):25-37. PubMed ID: 4943281
    [No Abstract]   [Full Text] [Related]  

  • 5. Late seroconversion following HPV-77, DE5 rubella virus vaccine.
    Wilkins J
    Am J Obstet Gynecol; 1975 Apr; 121(7):998-1002. PubMed ID: 1115189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic properties of RA27-3 rubella virus vaccine. A comparison with strains presently licensed in the United States.
    Plotkin SA; Farquhar JD; Ogra PL
    JAMA; 1973 Aug; 225(6):585-90. PubMed ID: 4740523
    [No Abstract]   [Full Text] [Related]  

  • 7. Trials with a live attenuated rubella virus vaccine, Cendehill strain.
    Grant L; Belle EA; Provan G; King SD; Sigel MM
    J Hyg (Lond); 1970 Sep; 68(3):505-10. PubMed ID: 5272349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroepidemiology of rubella and reinfection.
    Enders-Ruckle G
    Am J Dis Child; 1969 Jul; 118(1):139-42. PubMed ID: 5790241
    [No Abstract]   [Full Text] [Related]  

  • 9. "Rubella virus vaccine, live".
    Clin Pediatr (Phila); 1970 Dec; 9(12):15A passim. PubMed ID: 5487471
    [No Abstract]   [Full Text] [Related]  

  • 10. Combined live rubella-mumps virus vaccine. Findings in clinical-laboratory studies.
    Weibel RE; Stokes J; Villarejos VM; Arguedas JA; Buynak EB; Hilleman MR
    JAMA; 1971 May; 216(6):983-6. PubMed ID: 5108387
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibody response in school children to live rubella vaccine (Cendehill strain).
    Iwakata S; Elkerton LE; Rhodes AJ; Bull JA; Labzoffsky NA
    Can Med Assoc J; 1972 May; 106(9):980-2. PubMed ID: 4554732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical and serological study of women exposed to rubella vaccinees.
    Klock LE; Spruance SL; Bailey A; McQuarrie HG; Herbertson RM; Sharp HC; Smith CB
    Am J Dis Child; 1972 May; 123(5):465-8. PubMed ID: 4554618
    [No Abstract]   [Full Text] [Related]  

  • 13. Cendehill strain of rubella vaccine: clinical evaluation.
    Farquhar JD; Plotkin SA; Schoengold RJ
    J Pediatr; 1969 Sep; 75(3):412-7. PubMed ID: 5804187
    [No Abstract]   [Full Text] [Related]  

  • 14. Loss of rubella hemagglutination inhibition antibody in congenital rubella. Failure of seronegative children with congenital rubella to respond to HPV-77 rubella vaccine.
    Cooper LZ; Florman AL; Ziring PR; Krugman S
    Am J Dis Child; 1971 Nov; 122(5):397-403. PubMed ID: 5129528
    [No Abstract]   [Full Text] [Related]  

  • 15. Experimental active and passive immunization against rubella.
    Budai J; Tóth M; Melis L
    Acta Paediatr Acad Sci Hung; 1970; 11(3):209-17. PubMed ID: 4111953
    [No Abstract]   [Full Text] [Related]  

  • 16. [Characteristics of the reactogenic properties and effectiveness of live rubella vaccine].
    Iakovleva NV; Nasibov MN; Smorodintsev AA
    Vopr Virusol; 1969; 14(3):365-9. PubMed ID: 5820958
    [No Abstract]   [Full Text] [Related]  

  • 17. Vaccination with RA 27-3 rubella vaccine. Persistence of immunity and resistance to challenge after two years.
    Liebhaber H; Ingalls TH; Le Bouvier GL; Horstmann DM
    Am J Dis Child; 1972 Feb; 123(2):133-6. PubMed ID: 4554549
    [No Abstract]   [Full Text] [Related]  

  • 18. An open community trial of live rubella vaccines. Study of vaccine virus transmissibility and antigenic efficacy of three HPV-77 derivatives.
    Veronelli JA
    JAMA; 1970 Sep; 213(11):1829-36. PubMed ID: 4917635
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical manifestations, according to age, among females given HPV-77 duck rubella vaccine.
    Swartz TA; Klingberg W; Goldwasser RA; Klingberg MA; Goldblum N; Hilleman MR
    Am J Epidemiol; 1971 Sep; 94(3):246-51. PubMed ID: 5093654
    [No Abstract]   [Full Text] [Related]  

  • 20. Artificial challenge studies in rubella. Utilization of RA 27-3 rubella vaccines, rubella naturally acquired seropositives, and rubella susceptible children.
    Naficy K; Nategh R; Ahangary S; Mohsenin H
    Am J Dis Child; 1970 Dec; 120(6):520-3. PubMed ID: 5481902
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.